

**S6 Table. Pooled incidence rate of fatigue at entire of treatment**

| <b>Treatment comparison</b> | <b>No. of studies</b> | <b>No. of subjects</b> | <b>No. of having events</b> | <b>Rate (%) of fatigue (95% CI)</b> |
|-----------------------------|-----------------------|------------------------|-----------------------------|-------------------------------------|
| PR                          | 8                     | 482                    | 229                         | 50.0 (42.9, 57.1)                   |
| SMV plus PR                 | 4                     | 892                    | 383                         | 44.8 (37.7, 51.9)                   |
| DCV plus PR                 | 2                     | 353                    | 193                         | 54.7 (49.5, 59.9)                   |
| SOF plus PR                 | 2                     | 144                    | 86                          | 56.7 (34.8, 78.7)                   |
| SOF plus LDV                | 2                     | 862                    | 191                         | 22.2 (19.4, 24.9)                   |
| SOF plus DCV                | 1                     | 100                    | 39                          | 39.0 (29.4, 48.6)                   |
| PrOD                        | 1                     | 79                     | 16                          | 20.3 (12.0, 30.8)                   |
| SOF plus LDV with RBV       | 2                     | 650                    | 236                         | 36.3 (32.6, 40)                     |
| SOF plus DCV with RBV       | 1                     | 70                     | 24                          | 34.3 (23.2, 45.4)                   |
| PrOD with RBV               | 1                     | 40                     | 10                          | 25.0 (12.7, 41.2)                   |

CI, confidence interval; DCV, daclatasvir; LDV, ledipasvir; PR, pegylated interferon-ribavirin; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir